DOCSLIB.ORG

Supplement 12

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplement 12 CUMULATIVE SUPPLEMEMT ~ 2 JAH~90·DEC~90 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 10TH EDITION u.s. DEPARTMENT OF HEALTH AND HUMAN S:=RVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION SUBSCRIBE NOW! A vailable in March 1991 New 11th Edition APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 11th EDITION 1991 CONTENTS • Prescription Drug Product List • OTC Drug Product List • Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List • Discontinued Drug Product List • Orphan Drug Product Designations • Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution • Biopharmacetitic Guidance Availability • ANDA Suitability Petitions • Patent and Exclusivity Information See Subscription Form Inside Back Cover RX DRUG ,PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'90 - DEC'90 4 AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX ASPIRIN; MEPROBAMATE CAPSULE, EXTENDED RElEASEjORAL TABLETi ORAL BIPHETAMINE,12 •.5·, , 16~1 1~'~11~l~f1idl lit~;Jt~~~1 IJit~~~M-fI " ~~~~:i~~~~~~~~~Y /~;i.d.d~~/.d# / /rs.~~1:~1~i~:~~ BJ;PHETAMINE 20 Ci) VITARINE 325MGi200MG N89127 001 FISONS EQ 10MG'BASE; MAR 02, 1987 EQ 10MGBASE NI0093 003 IJit~f..tjl I ~dl;id ~¢/dk~'nl ,", 1~~n~:~¢/~.(;~i /~;i~~!J~/.d~d~/ ASPIRIN; O~CODONE HYOROCHLORIDE; OXYCODONE TEREPHTHALATE BIPHETAMINE 7 . .5 FISONS •E~ 3. ~5MG"iBA~E; , TABLET; ORAL "I;Q '3,,,,7SMG'BASE " NI0093 (109 Ol<YCODONE AND ASPZRZH /Jit~~Af-jj It(VJ.:j~rs.¢lJ:1X#Jl AA BARR LABS 325MG;4.5MG;~ N87794 001 It~r;'::j~rs.¢/J:1A<)U /~;i.d~!J~/.d.d!J/ HAY 26, 1982 16~i6ddd~t'~~ttBiHI IAAI -7~~~~7~~~~1 - lit~cl~;~~~~;~§~~1 ANIAZOLINE PHOSPHATE; NAPHAZOLINE ""()ROCtlLORIDE Irs.~~n~~%~:~~ SOLUTION/DROPS;' OPHTHiLMIC ATENOLOL VA~~~:"':HARMS O.5%;0.Q5;?1i N18,746 001 APR 30, 199,0 TABLET; ORAL TENORMIN ICI PHARM 25MGn N18240004 ASPIRIN; BUTALBITAL; CAFFEINE;' CODE'INEPHOSPHATE APR 09, 1990 CAPSULEi ORAL FIORlNAL H/CODEINE NO 3 ATENOLOL; CHlORTHALIDONE SANDOZ 325MGi50MGi40MGi3()MGil N19429 003 OCT 26, 1990 TABLET; ORAL ATEtlOLOL AND CHLORTHAL%DONE AB ' ICI PHARMS 50MG i 25MGII N72301 001 ASPIRIN; CAFFEINE; ORP,HENADRINE CITRATE HAY 31, 1990 ~ lQQt:l2i~ N72302 001 TABLET; ORAL ,'," , ',' '.' ' MAY 31, 1990 TEHOR!T%C 100 h~~/~'~j~~~~~t!¢~!~~~I~~~~¢Jj~~,U~~rs.¢/ /~j~~~,t~~~11 ~ STUART PHARMS 100MGi25MG N18760 001 / J~/I'-~.• /,... pp JUN 08, 1984 a VITARINE 38.5,tiGi 30M~;i 25MG' N71564 001 TEHOR!T%C 50 JUNZ3,1988 AB STUART PHARMS a.ru:12;25MG N18760 002 JUN 08, 1984 /~~/~~~~~~~,i/~~~I~~~~~~~~a~~~~;, IJ~~~~~1%~~a~ aVITARINE 770MG;60~)50MG N71565 001 ATROPINE SULFATE JUN 23, 1988 AEROSOL, METEREDiINHALATION , ATROPINE SULFATE DEPT ARMY EQ 0.36MG,BASE/IN~" N20056 001 SEP 19, 1990 -,,' " '/ RX DRUG PRODUCT LIST 1 CUMULATIVE $UPPtEMfHT NUMBER 121 JAN'90 - DEC'90 5 ATROPINE SULFATE> DIPHENOXVLATE HYDROCHLORIDE BACLOFEN TABLET; ORAL TABLET; ORAL . D%PHEHQKXLATEHCL AHD ATRO~E SULFATE > DL T > . 1':tdIfIf"'.,:n!l1 AA MYLAN PHARM$ 0.025I1G;2.5MG N85762 001 > DLT >/6DI ~~tj~J7~~A~I'l~1 I~I liil I~A~~t/~X#.~1 /a;~gtri~1 1~1>.1t'JtI.6.6U > DLT > a PARKE DAVIS. 0,;025I'1G.;2-/5MG. N87131 001 1.J~~7~~~~~~~~ '. .1r1tP.tJ~tld11f~t1}6' 'tJat!Mp.:t~~ili1tl I Iii . If'1j~~lp~A~/'l. 7Llg~cl§.{t,]rJGI 1~1>~.1('1./.6#1 >~> BEPRIDIL HYDROCHLORIDE > ADD > TABLET; ORAL ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE > ADD > BEPAD:EH > ADD> A§ HALLACE 200MGaI N19001 001 INJECTABLE; INJECTION > ADD > DEC 28, 1990 ATRoPl:HE .AHDDEHEROL > ADD> AB ~ N1900.1 002 16P.! ./#t~f;t~td#~¢1 la;~ld'(.tdtf;ltb;t Jr;.1I>~;J,/~#J > ADD > - DEC 28, 1990 > ADD> A§ 400MGaI N19001 003 laP.! I~Ghl'ft.tri~'1 '~~~~~AA~~~~~ > ADD> DEC 28, 1990 1~~11f.~ .• ff~n >..A!llL> VASCOR laP.! 1~ltb;.fillr:JrUtb;1 > ADD> A§ RH JOHNSON 200MGaI N19002 001 I~~~~~~~~:~~ > ADD> DEC 28, 1990 STERLING DRUG 0.4MG/ML;50MG/ML :N87853 .001 >-AJllL> AB llruLGai N19002 002 NO't26" 1982 > ADD > DEC 28, 1990 Oi4MG/ML;75MG/ML N87847 001 > ADD). A§ 400MGa N19002 003 NOV 2~, 1982 > ADD > DEC 28, 1990 0~4Mt;/ML;100MG/ML N87848 001 NOV 26, 1982 MEPER%D:EHE AHD ATROP:EHE, SULFATE BETAMETHASONE DIPROPIONATE /~:ftJtllm~#/UW '~4~!lt ~~~~~~~~.~~~ CREAM; TOPICAL ,~~ mf.#,.#/~~"J1 BETAME111ASOHE DXPROPJ:OHATE Gl WYETH AYERST LABS 0;·4MG/ML;50M(;/ML . N85121 001 A§ CLAY PARK LABS EQ 0,05% BASEa N72536 001 Gl O.4MG/ML;75MG/ML ~85121 Q02 JAN 31, 1990 Gl 0"4I'1G/ML; 100MG/ML N85121 003 LOTIOm TOPICAL BETAMrn1ASOHE DXPROPXOHATE BACLOFEN AB CLAY PARK LABS EQ 0.05Y. BASEa N72538 001 JAN 31, 1990 TABLET; ORAL BACLOFEN OINTMENT; TOPICAL I~~I 1~;tfA~;t~tl n.61'l¢1 mjj.Mf./~6U BETAMETHASOHE DXPROPJ:OHATE AS CLAY PARK LABS EQ 0.05Y. BASEa N72526 001 I~~/ 11..61'l¢( I A~~~.,j.. j. .•... ~:~.~'•... 9i,~~I!~ JAN 31, 1990 '~ .:. :: ~.\. :, "." ..... IA~~VJ~::ij.~~~1 .)~rrAItINE 10MG N71901001 : ." . , . ~. APR 13, 1988 BROMPHENIRAMINE MALEATE Gl 20MG::;' N71902 001 AP,R~3, 1988 INJECTABLE.; INJECTION > ADD > UORE5AL BROMPHENIRAMINE MALEATE· 20MG .. > ADD > AB "GEIGY;PHARMS ,N17851 003 l~ft~j~/tA~~1 1j.~~I'l¢;l'lt/ I~I! ~1!~.61.6.6 j./ > ADD > JAN 20, 1982 a STERIS LABS 100MG/ML N83820 001 PRODUCT LIST I CUMULATIVE SUPPLEMENT NUMBER 12 I JAN'90 - DEC'90 12 CLORAZEPATE,DIPDTASSIlJM CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE , ' , TABLEHORAL , l;t~)t¢#~~t,;'/;t~)t¢f;t~/ CLORAZEPA'rE' D:EPOTASs;tU1 ~ CORD LABS' 3 .• 7SMGA N72512 001 IP7~~~~I1~/~~~~'V 1.6 :ptf¢MtJ~.:f.tf¢/tlt {f MAY 11, 1990 Ij.~¢/tftl ' /~j.j.~#/~,6j./ ~7.SMGA N72S13 001 a ARMOUR PHARM 0.SMG/ML;2.3MGIML; MAY 11, 1990 IMG/ML N11208 001 AS lSMGA N72514 001 MAY 11, 1990 CYCLOSPORINE' CLOTRIMAZOLE' CAPSULE; ORAL SANDIMMUNE CREAM; VAGINAL SANDOZ PHARMS 25MGA NS062S 001 MAR 02, 1990 16tl IS~~~~~l~a;~1 1f.31 1~j.~~~~1.6,6j./ 100MGA NS0625 002 ~CELE)(.G . MAR 02, 1990 I Ail' ~t1ttt~N~~~I'V Ittl I~j.~~f.~/#j./ MIL.ESPHARM 1% N18230 001 CYPROHEPTADINE HYDROCHLORIDE TABLET; VAGINAL TABLET; ORAL I 'tI"/rJ~~~~f~!~~tV 11J.~~rJl I~j.jjj.j1.6,6j./ CY~ROHEPTAD:EHE HCL MYCELE)(.G 1"1 I ~/~~A~t1I I~HrJl 1~~~jf..1I.d,dj./ /6tl /t1ttt~7~~~~~1 /1.~~HrJ/ /~j.M~M,6,6j./ a KV PHARM 4MG N86737 001 MILES PHARM 100MG N18182 001 > DLT >/"/ /~Il~t~~~~~~/ I~~I /~~Ht~~/~#/ > ADD > a SUPERPHARM 4MG N87405 001 CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE CYTARABINE SYRUP; ORAL INJECTABLE; INJECTION CYTARABINE 1"1 Il"~j1~~~gf 11.1tcl~l~~Jj~': (f BULL LABS 20MGIML~ N71868 001 JUN 04, 1990 Il&jHj21JffJ----~ 1~~~~~J'i~~~~ 20MGIML~ N72168 001 TR%PROL%D:EHE HCL. PSEUDOEPHEDR:tHE HCL AHD CODEEHE' AUG 31, 1990 PHoSPHATE ' AA PBI 10MG/SML;30MG/SML; 1.2SMG/SML N88833 001 > ADD > DAPIPRAZOLE HYDROCHLORIDE NOV 16, 198,4 >..A!llL> SOLUTION/DROPS; OPHTHALMIC >..A!llL> REV-EYES >.Jt!.L.> Icq(t6S~E,R~(~p.A,(~ttA#./ '. > ADD > ANGELINI PHARMS 0.5~ N19849 001 >..A!llL> DEC 31, 1990 ~ .~t~ ~ /~~~~a~~~%~a~~~~~yl1#~~h";t~~~~~¢~t~tI >..J!!..L > . "#Il~~~Il¢~#~Ut~1 ;fj.lJ~~r)N;t~p.l/ > DLT > . I ~~~':~~17i~:~~~ RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'90 - DEC'90 13 DESIPRAMINE HYDROCHLORIDE DEXAMETHASONE TABLET; ORAL TABLET; ORAL DESIPRAMINEHCL DEXAMETHASONE I~U N~t~~t~t/ fj.~~¢1 If'~j~~~%~~~~ Ci) BARR LABS 0.5MG N84766 001 I~~I Itf;M¢1 1~}~~.~XI~:6f DEXAMETHASONE SODIUM PHOSPHATE '/~U /f;.6~¢1 IJ~~1~~~~76~l IJ~~~~f;,~~;t~~.111 INJECTABLE; INJECTION I~~I lJf;~¢1 I". ,L~. ,f-I .. ;t DEXAMETHASOHE SOD::tU1 PHOSPHATE IAll /j..~ttl~tpftVM~1 7t~..:.g~l'kt!d.~MthK/ 1./~~/~~~tlt~.6{11 I~# fj..6~6~¢1 1~7~~1~~~7a~~~ rtp ;t. o' ,L.~. It)(.t Nf; .• ~;(jf,j I ., INTL MEDTN SYS EQ 20MG PHOSPHATE/ML N88522 001 I~~I fj.f;.6~¢1 FEB 17, 1984 AI!. KENDALL MCGAH EQ 4MG PHOSPHATE/Mo. N81125 001 Ci)'VITARINE 10MG If'~~~~f:A~~B~N72167 00.1 AUG 31, 1990 FES03j'1988 AP EQ 10MG PHOSPHATE/M~ N81126 001 a 25MG N7160.1 .001 AUG 31, 1990 JUN05, 198.7 Ci) 50MG N71S88:001 OINTMENT; OPHTHALMIC JUN 05, 1987 HAKXDEK . ., , 75MG N71602 001 AT ALCON LABS EQ 0.05% PHOSPHATE N83342 001 OCT 05, 1987 ai, 100MG N71766 001 OCT 05, 1987 't)j~Z1~~lV,t).t1~~,(~;t¢·:'t)t;t¢' a 150MG N.72254 001 lat! I 7A~¢~~~t'(~~1 It~~~~~!dAttl I~~~~,t/~~;tl FE~03, 19.88 '~t)~~~~~1~~~f~~:ru,(~~~iptlt' DESMOPRESSIN ACETATE IAtl I 7~j~~;t~nA~~r--t-~-!/i -. !J ~.1d~~Ed6ttl IJ~~'1~~%~:~~ SOLUfioNP·NASAL ' > ADD > CQNCENTRAID SOLUTION/DROPS; OPHTHALMIC, OTIC > ADD >FERRING LABS 0'.01X. DEXAMEnlASOHE SOD:tU1 PHOSPHATE >-AR!L> DE~lir~~l~~~ AT STERIS LABS Elr 0.1% PHOSPHATE N88771 001 JAN 16. 1985 PESOXIMETAsONE PEXTROAMPHETAMINE SULFATE CREAtH' TopICAL' .. DESO>aMETASOHE >...P.!.I...> AS . "'TARO PHARMS 0.05%)1 N73210 001 > DLT > 1¢1~~~~;'~1~tI NOV .3.0, 1990 > DLT > Ittt1t1t)~1 '. 1tf;~¢1 1~~f;~f;f;1.6~j.f M 0.25%)1 N73193 :001 >-AR!L> Ci) LEMMON 15MG N85355 001 NOV/3D:, '. 19'9(r TOP%CORI AS .HOECHST 0.257. N17856 001 TOP%CORT:!LP :~,,~~,. AB ,0 HOECHST ():05% N18309 001 ";'." "."; '."~ " · >.,.,." >. ' .. ,' •.' .,', ~-_'. -.,_-, -"_~, '.'__ , ....... ' •• "'.- ,,~ •• -....;::..~. ~.-..J\ .... ,-..... ::'"..l"..... ~~~....... 'J.l!"_-';'"l'.'!I:':"::'I..O:.J..~1"~"'.1'_:;.Y."'_'Jt"':~'"i.~Z~~~'o:..<~,;It'~:-17.
Load more

Recommended publications
  • Identifying the Defendant in Products Liability Litigation: Alternate Theories for Compensating Injured Plaintiffs
    International Journal of Business and Social Science Vol. 9 • No. 8 • August 2018 doi:10.30845/ijbss.v9n8p2 Identifying the Defendant in Products Liability Litigation: Alternate Theories for Compensating Injured Plaintiffs Richard J. Hunter, Jr. Professor of Legal Studies Seton Hall University United States John H. Shannon Professor of Legal Studies Seton Hall University United States Henry J. Amoroso Associate Professor of Legal Studies Seton Hall University United States Abstract A spirited public policy debate has raged in the United States for more than four decades revolving around the responsibility of drug manufacturers for their products that cause injury to unsuspecting plaintiffs. An important part of the debate centers around a drug—DES—that was marketed as a benefit to women in preventing miscarriages. Some interesting or "alternate" theories for assessing liability have received attention in the generic area of products liability. This article will discuss three of the most prominent and still controversial theories—alternative liability, enterprise liability, and market share liability. In addition, the article will include several case studies exemplifying the legal principles discussed — some coming to very difficult conclusions — regarding the efficacy and application of these theories to particular facts developed during litigation. Keywords: Alternative Liability; Enterprise Liability; Market Share Liability 1. Introduction DES (Diethylstilbestrol, a synthetic form of the female hormone estrogen) litigation in the United States has been both extensive and controversial. Forty years ago, at the height of the DES crisis, in a seminal law review article in the Fordham Law Review, Sheiner (1978) estimated that the number of women who took DES during pregnancy ranged from 1 1/2 million to 3 million.
    [Show full text]
  • List of Marginable OTC Stocks
    List of Marginable OTC Stocks @ENTERTAINMENT, INC. ABACAN RESOURCE CORPORATION ACE CASH EXPRESS, INC. $.01 par common No par common $.01 par common 1ST BANCORP (Indiana) ABACUS DIRECT CORPORATION ACE*COMM CORPORATION $1.00 par common $.001 par common $.01 par common 1ST BERGEN BANCORP ABAXIS, INC. ACETO CORPORATION No par common No par common $.01 par common 1ST SOURCE CORPORATION ABC BANCORP (Georgia) ACMAT CORPORATION $1.00 par common $1.00 par common Class A, no par common Fixed rate cumulative trust preferred securities of 1st Source Capital ABC DISPENSING TECHNOLOGIES, INC. ACORN PRODUCTS, INC. Floating rate cumulative trust preferred $.01 par common $.001 par common securities of 1st Source ABC RAIL PRODUCTS CORPORATION ACRES GAMING INCORPORATED 3-D GEOPHYSICAL, INC. $.01 par common $.01 par common $.01 par common ABER RESOURCES LTD. ACRODYNE COMMUNICATIONS, INC. 3-D SYSTEMS CORPORATION No par common $.01 par common $.001 par common ABIGAIL ADAMS NATIONAL BANCORP, INC. †ACSYS, INC. 3COM CORPORATION $.01 par common No par common No par common ABINGTON BANCORP, INC. (Massachusetts) ACT MANUFACTURING, INC. 3D LABS INC. LIMITED $.10 par common $.01 par common $.01 par common ABIOMED, INC. ACT NETWORKS, INC. 3DFX INTERACTIVE, INC. $.01 par common $.01 par common No par common ABLE TELCOM HOLDING CORPORATION ACT TELECONFERENCING, INC. 3DO COMPANY, THE $.001 par common No par common $.01 par common ABR INFORMATION SERVICES INC. ACTEL CORPORATION 3DX TECHNOLOGIES, INC. $.01 par common $.001 par common $.01 par common ABRAMS INDUSTRIES, INC. ACTION PERFORMANCE COMPANIES, INC. 4 KIDS ENTERTAINMENT, INC. $1.00 par common $.01 par common $.01 par common 4FRONT TECHNOLOGIES, INC.
    [Show full text]
  • V. : Civil Action No. DKC 14-3607
    Case 8:14-cv-03607-DKC Document 47 Filed 07/29/15 Page 1 of 73 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND : MALLINCKRODT INC. : v. : Civil Action No. DKC 14-3607 : UNITED STATES FOOD AND DRUG ADMINISTRATION, et al. : MEMORANDUM OPINION Plaintiff Mallinckrodt Inc. (“Mallinckrodt”), a pharmaceutical manufacturer, brings this action seeking judicial review of actions taken by the United States Food and Drug Administration (“FDA”), regarding its methylphenidate hydrochloride extended-release tablets, a generic version of the brand-name drug Concerta. Presently pending and ready for review in this action are several motions: (1) a motion to dismiss filed by Defendants FDA and United States of America (“Defendants”) (ECF No. 30); (2) a motion to compel production of the administrative record filed by Mallinckrodt (ECF No. 31); (3) a motion for summary judgment filed by Mallinckrodt (ECF No. 34); and (2) two motions to seal filed by Mallinckrodt (ECF Nos. 4 and 20). The relevant issues have been briefed, and the court now rules, no hearing being deemed necessary. Local Rule 105.6. For the following reasons, Defendants’ motion to dismiss will be granted in part, and summary judgment will be granted in part Case 8:14-cv-03607-DKC Document 47 Filed 07/29/15 Page 2 of 73 against Plaintiff. Mallinckrodt’s motion to compel production of the administrative record will be denied as moot, and Mallinckrodt’s motions to seal will be denied. I. Background A. Statutory and Regulatory Background The FDA regulates the approval, manufacture, sale, and labeling of prescription drugs.
    [Show full text]
  • Brief of Consumers Union of United States, Inc., As Amicus Curiae in Support of Petitioners, Riegel & Riegel V
    Georgetown University Law Center Scholarship @ GEORGETOWN LAW 2007 Brief of Consumers Union of United States, Inc., as Amicus Curiae in Support of Petitioners, Riegel & Riegel v. Medtronic, Inc., No. 06-179 (U.S. Aug. 27, 2007) Lisa Heinzerling Georgetown University Law Center Docket No. 06-179 This paper can be downloaded free of charge from: http://scholarship.law.georgetown.edu/scb/40 This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author. Follow this and additional works at: http://scholarship.law.georgetown.edu/scb Part of the Consumer Protection Law Commons, and the Torts Commons No. 06-179 ~ ~!~! GLE~a~K IN THE £ upreme ¢£ourt of nite tate CHARLES R. RIEGEL AND DONNA S. RIEGEL, Petitioners V. MEDTRONIC, INC., Respondent ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT BRIEF OF CONSUMERS UNION OF UNITED STATES, INC., AS AMICUS CURIAE IN SUPPORT OF PETITIONERS LISA HEINZERLING Counsel of Record 600 New Jersey Ave., N.W. Washington, D.C. 20001 (202) 662-9115 MARK SAVAGE Consumers Union of United States, Inc. 1535 Mission Street San Francisco, CA 94103-2512 Counsel for Amicus Consumers Union of United States, Inc. WILSON-EPES PRINTINGCO., INC. - (202) 789-0096 - WASHINGTON, D. C. 20002 QUESTION PRESENTED Whether the express preemption provision of the Medical Device Amendments to the Food, Drug, and Cosmetic Act, 21 U.S.C. § 360k(a), preempts state-law claims seeking damages for injuries caused by medical devices that received premarket approval from the Food and Drug Administration.
    [Show full text]
  • The Life Cycle of Sterling Drug, Inc.*
    22 Bull. Hist. Chem., VOLUME 25, Number 1 (2000) THE LIFE CYCLE OF STERLING DRUG, INC.* Joseph C. Collins and John R. Gwilt The foundations of Sterling Drug were laid by William partners were bought out. Weiss and Diebold realized E. Weiss and Albert H. Diebold, boyhood friends in that expansion required more product lines and that these Canton, Ohio. Weiss graduated from the Philadelphia would best be obtained by acquisition. This policy con- College of Pharmacy in 1896 and went to work in a tinued throughout the life of the organization, at least drug store in Sistersville, West Virginia. Diebold raised 130 companies being acquired, directly or indirectly, funding from his father’s company, Diebold Safe and Lock, and in 1901 the friends set up business together in Wheeling, WV. In fact, Sterling operated a plant in that town until 1962. The history of the Corporation can conveniently be divided into five periods: 1901-1917 The Neuralgyline Period 1917-1928 Sterling Products I 1928-1933 Drug Inc. 1933-1942 Sterling Products II 1942-1988 Sterling Drug, Inc. The Neuralgyline Period On May 4, 1901, Weiss and Diebold, with three local business men as partners, established the Neuralgyline Company with the sole purpose of manufacturing and Figure 1. Where it all began: in 1901 the selling a pain-relieving preparation which they called Neuralgyline Company occupied two upstairs rooms “Neuralgine.” There is now no company record of its in this house in Wheeling, WV. composition, but it seems to have been a mixture of ac- from 1902 through 1986. Ironically, the eventual fate etanilide, caffeine, and sodium salicylate.
    [Show full text]
  • Pharmaceutical Sector
    MARKET REVIEW ON PRIORITY SECTOR UNDER COMPETITION ACT 2010 PHARMACEUTICAL SECTOR Malaysia Competition Commission (MyCC) 27 December 2017 TABLE OF CONTENTS Executive Summary 2 List of Abbreviations 7 Glossary 9 Introduction 16 Methodology and Limitations 18 Policy Context for the Review 24 PART ONE: OVERVIEW OF MALAYSIA’s PhARMACEUTICAL SECtor Chapter 1: Overall Growth of the Healthcare and Pharmaceutical Sectors 28 Chapter 2: Market Structure and Supply Chain 41 Chapter 3: Market Share and Market Concentration 69 Chapter 4: Market Dominance and Impact on Availability, Affordability and Accessibility of Medicines 93 PART TWO: COMPETITION CONCERNS IN THE PHARMACEUTICAL SECtor Chapter 5: Key Existing Laws and Regulations and An Assessment of Impacts 118 Chapter 6: Competition Concerns Among Industry Players 148 Chapter 7: Selected Case Studies on Anti-Competitive Conduct 177 PART THREE: CONCLUSION AND RECOMMENDatIONS Chapter 8: Conclusion and Recommendations 208 APPENDICES Appendix 1: Guiding Questions for Interviews with Industry Players 224 Appendix 2: Malaysian Organization of Pharmaceutical Industries (MOPI) Members 229 Appendix 3: Brief Profiles of Top 6 Malaysian Local/Joint Venture Pharmaceutical Companies 230 Appendix 4: Pharmaceutical Association of Malaysia (PhAMA) Members 232 Appendix 5: Malaysian Association of Pharmaceutical Suppliers (MAPS) Members 233 Appendix 6: Drug Registration Process 234 References 236 EXECUTIVE SUMMARY The aims of Malaysia’s National Medicines Policy are to promote equitable access to, and rational use of, safe, effective and affordable medicines by its population. In order to maximize social welfare, this policy is strengthened by Malaysia’s Competition Act of 2010 and the establishment of the Malaysia Competition Commission (MyCC) to bring about allocation, production and innovation efficiencies.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Healthcare & Life Sciences Industry Update
    Healthcare & Life Sciences Industry Update August 2011 Member FINRA/SIPC www.harriswilliams.com What We’ve Been Reading August 2011 • The biggest story from inside the Beltway over the last month was the battle and eventual deal to raise the U.S. debt ceiling to avoid an impending August 2nd default. The Budget Control Act of 2011 will raise the debt ceiling by $2.1-$2.4 trillion, while reducing spending by approximately $2.1 trillion over the next decade. In an interesting post-deal analysis, Michael Hiltzik of the Los Angeles Times notes that despite the protracted negotiations over a broad spectrum of cost-cutting measures, healthcare was not raised as a primary issue. Some have found this especially concerning, considering the outsized portion of the Federal Budget currently allocated to healthcare spending, which is forecast to rise in the coming years. A recent article in The Economist, entitled “Looking to Uncle Sam” makes this point and goes further to suggest that Centers for Medicare & Medicaid Services (CMS) actuaries may be underestimating future increases in Medicare and Medicaid spending. • One potential reason CMS actuaries may be underestimating the future costs of Medicare and Medicaid relates to healthcare reform’s effect on employee benefits, and specifically, the 2014 switch to subsidized exchange policies. A recent report by McKinsey & Company estimates that approximately 30% of employers will stop offering employer- sponsored insurance (ESI) when this switch is made, as opposed to the 7% estimated by the Congressional Budget Office. An ESI exodus of this magnitude could cause substantial strain on an already robust government healthcare budget.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • ACC.17 Program Committee Disclosures.Xlsx
    ACC.17 Program Committee Disclosures of Relationships With Industry Name Disclosures Brian G. Abbott, MD, FACC Nothing to Disclose J. Dawn Abbott, MD, FACC DATA SAFETY MONITORING BOARD - Pfizer Nazem Akoum, MD, FACC CONSULTANT FEES/HONORARIA - Biotronik Karen P. Alexander, MD, FACC CONSULTANT FEES/HONORARIA - Gilead Sciences, Inc.; DATA SAFETY MONITORING BOARD - CytRx; RESEARCH/RESEARCH GRANTS - gilead, Regeneron, Sanofi Aventis Mouaz H. Al-Mallah, MD, FACC CONSULTANT FEES/HONORARIA - GE Healthcare; SPEAKER’S BUREAU - Pfizer Inc, Philips Jesus G. Almendral, MD, FACC Nothing to Disclose Aimee K. Armstrong, MD, FACC CONSULTANT FEES/HONORARIA - B. Braun Interventional Systems Inc., Edwards Lifesciences, Siemens Healthcare AX, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC Herbert D. Aronow, MD, MPH, Nothing to Disclose FACC Samuel J. Asirvatham, MBBS, CONSULTANT FEES/HONORARIA - Abiomed, AtriCure, Biosense Webster, Biotronik, FACC Boston Scientific, Elsevier, Medtelligence, MEDTRONIC, Sanofi Aventis, St. Jude Medical, Wolters Kluwer, Zoll Alison Bailey, MD, FACC RESEARCH/RESEARCH GRANTS - CSL Behring Subhash Banerjee, MD, FACC CONSULTANT FEES/HONORARIA - Boston Scientific; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Mdcare Global LLC; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation; SPEAKER’S BUREAU - CSI, MEDTRONIC Geoffrey D. Barnes, MD, FACC CONSULTANT FEES/HONORARIA - Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of Michigan, BMS/Pfizer Theodore A. Bass, MD, FACC Nothing to Disclose
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • Preliminary Guide to the Parke, Davis Research Laboratory Records
    Preliminary Guide to the Parke, Davis Research Laboratory Records NMAH.AC.0001 Robert Harding 1983 Archives Center, National Museum of American History P.O. Box 37012 Suite 1100, MRC 601 Washington, D.C. 20013-7012 [email protected] http://americanhistory.si.edu/archives Table of Contents Collection Overview ........................................................................................................ 1 Administrative Information .............................................................................................. 1 Biographical / Historical.................................................................................................... 3 Arrangement..................................................................................................................... 3 Scope and Contents........................................................................................................ 3 Names and Subjects ...................................................................................................... 4 Container Listing ............................................................................................................. 5 Series 1: Corporate Materials, 1887-1951............................................................... 5 Series 2: Financial Materials, 1880-1970............................................................... 11 Series 3: Employee/Personnel Materials, 1900-1989............................................ 12 Series 4: Advertising/Sales Materials, 1868-1980.................................................
    [Show full text]